News & Research
New studies, trials, regulatory changes and news about the compounds on Amino Reference. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-05.
- The Week Progress Got More Specific
Vastkind
A briefing on the TRIUMPH-2 diabetes trial of retatrutide (GLP3-R) separates an 18.8% treatment-regimen weight-loss figure from a 20.8% efficacy estimate. It also notes a planned United States filing in early 2027, which is a regulatory step and not an approval.
- CagriSema Curbs 'Food Noise,' Organ Fat in Patients With Obesity, T2D Respectively
Pharmacy Times
EASD abstracts reported that cagrilintide plus semaglutide changed brain responses to high-calorie food cues and reduced liver and pancreas fat. An FDA weight-management decision is expected in the fourth quarter of 2026, so the pages should record that timeline without treating conference abstracts as a full regrade.
- Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
Pharmacy Times
Phase 3 TRIUMPH-2, published in The Lancet, found retatrutide, sold in research channels as GLP3-R, cut weight by up to 18.8% at 80 weeks in type 2 diabetes, with more hypotension and dysesthesia. Lilly is aiming at an FDA filing in early 2027, which is not an approval.
- Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
ScienceAlert
The NEJM TRIUMPH-1 trial reported about 25% weight loss at 80 weeks on retatrutide 12 mg in obesity without diabetes, and nearly 30% in a smaller two-year extension. That non-diabetes result should be stated separately from the type 2 diabetes trial on the GLP3-R page.
- New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
MedPage Today
ACHIEVE-4 found orforglipron noninferior to insulin glargine for MACE-4, 4.2% versus 5.0%, hazard ratio 0.84, but it was not powered to prove a cardiovascular benefit. The orforglipron page should call this a heart-safety comparison, not evidence that the pill prevents cardiovascular events.
- Orforglipron Noninferior to Insulin Glargine for Cardiovascular Outcomes in T2D
Medscape
The same ACHIEVE-4 readout found better A1c and weight than insulin glargine, while gastrointestinal events drove discontinuation in 15.4% versus 5.4%. Those tolerability figures belong in the orforglipron safety section beside the cardiovascular result.
- Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
BMJ
BMJ reported phase 3 retatrutide results suggesting weight loss of up to 25%. Use it as a journal pointer for GLP3-R, and prefer the primary trial paper for dose, duration, and population.
- Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
Pharmacy Times
A Lilly-funded cross-trial model, not a head-to-head study, linked orforglipron 17.2 mg to about 1.5% more weight loss and 0.3% more A1C reduction than oral semaglutide 25 mg. The site should not upgrade comparative claims from this indirect sponsored analysis.